Literature DB >> 20658590

Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient.

Cristina Papayannidis1, Ilaria Iacobucci, Maria Chiara Abbenante, Antonio Curti, Stefania Paolini, Sarah Parisi, Michele Baccarani, Giovanni Martinelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20658590     DOI： 10.1002/ajh.21719

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  4 in total

Review 1.  Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.

Authors:  Meghavi Kathpalia; Pinki Mishra; Ram Bajpai; Dinesh Bhurani; Nidhi Agarwal
Journal:  Ann Hematol       Date:  2022-06-21       Impact factor: 4.030

2.  Nelarabine in the treatment of refractory T-cell malignancies.

Authors:  Andrew M Roecker; Amy Stockert; David F Kisor
Journal:  Clin Med Insights Oncol       Date:  2010-12-01

3.  Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication.

Authors:  Maria Chiara Tisi; Giuseppe Ausoni; Maria Gabriella Vita; Tommaso Tartaglione; Mario Balducci; Luca Laurenti; Patrizia Chiusolo; Stefan Hohaus; Simona Sica
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-03-01       Impact factor: 2.576

4.  Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.

Authors:  Annalisa Lonetti; Alessandra Cappellini; Alice Bertaina; Franco Locatelli; Andrea Pession; Francesca Buontempo; Camilla Evangelisti; Cecilia Evangelisti; Ester Orsini; Laura Zambonin; Luca Maria Neri; Alberto Maria Martelli; Francesca Chiarini
Journal:  J Hematol Oncol       Date:  2016-10-24       Impact factor: 17.388
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.